December 17, 2024 09:59 AM EST
R&D

UCB, No­var­tis say a Phase 2a Parkin­son's study failed

Max Gelman

Senior Editor

UCB and No­var­tis end­ed de­vel­op­ment on the lead pro­gram in their part­ner­ship af­ter re­port­ing a Phase 2a fail­ure in Parkin­son’s dis­ease.

The com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Chica­go’s biotech scene is grow­ing up. What’s fu­el­ing it?

Mer­ck winds down TIG­IT, LAG-3 pro­grams meant to tem­per Keytru­da ero­sion

Te­va and Sanofi step on the gas with an­ti-TL1A in IBD

FDA re­jects J&J’s sub­cu­ta­neous Ry­bre­vant over man­u­fac­tur­ing is­sues

Ex­clu­sive: Cell ther­a­py start­up Shi­no­bi adds Borges as sci­ence chief, Katz as top med­ical of­fi­cer

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

A service from the Financial Times